Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 49 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Makras, Polyzois [Clear All Filters]
Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study..
Endocrine. 81(3), 573-578.
(2023). The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis..
Calcif Tissue Int.
(2023). Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study..
J Clin Med. 12(16),
(2023).
(2023).
(2023).
(2022).
(2022).
Circulating microRNAs Related to Bone Metabolism in HIV-Associated Bone Loss..
Biomedicines. 9(4),
(2021).
(2021). Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation..
Calcif Tissue Int.
(2021). The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation..
J Clin Endocrinol Metab.
(2021). Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation..
J Clin Densitom.
(2021). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Ιrisin levels in postmenopausal women with an incident hip fracture..
Endocrine. 73(3), 719-722.
(2021). Combination and sequential treatment in women with postmenopausal osteoporosis..
Expert Opin Pharmacother. 21(4), 477-490.
(2020). Experience gained from the implementation of the fracture liaison service in Greece..
Arch Osteoporos. 15(1), 12.
(2020).
(2020).
(2020). Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview..
Hormones (Athens). 18(1), 65-70.
(2019). Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society..
Bone. 127, 401-418.
(2019). Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass..
J Musculoskelet Neuronal Interact. 19(3), 253-257.
(2019). Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment..
Bone. 120, 44-49.
(2019). Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?.
Metabolism. 93, 100-102.
(2019). Off-label uses of denosumab in metabolic bone diseases..
Bone. 129, 115048.
(2019).
(2019).